Dynamic contrast enhanced-MRI (DCE-MRI) as a pharmacodynamic biomarker for pazopanib (PZ) in metastatic renal carcinoma (RC).

被引：0
|
作者：
Sweis, Randy F.
Medved, Milica
Towey, Shannon
Karczmar, Greg S.
Oto, Aytekin
Szmulewitz, Russell Zelig
O'Donnell, Peter H.
Fishkin, Paul A. S.
Stadler, Walter Michael
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Illinois CancerCare, Peoria, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15623
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15623
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma
    Sweis, Randy F.
    Medved, Milica
    Towey, Shannon
    Karczmar, Gregory S.
    Oto, Aytekin
    Szmulewitz, Russell Z.
    O'Donnell, Peter H.
    Fishkin, Paul
    Karrison, Theodore
    Stadler, Walter M.
    [J]. CLINICAL GENITOURINARY CANCER, 2017, 15 (02) : 207 - 212
  • [2] Dyamic contrast enhanced MRI (DCE-MRI) pharmacodynamic (PD) study of sorafenib in metastatic renal cell carcinoma (RCC): Results of a randomized, phase II trial
    hahn, O. M.
    Yeng, C.
    Medved, M.
    Karczmar, G.
    Kistner, E.
    Manchen, B.
    Mitchell, M.
    Karrison, T.
    Ratain, M.
    Stadler, W. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase I study of Pazopanib (PAZ) in Hepatocellular Carcinoma (HCC): evaluation of clinical activity, Pharmacokinetics (PK), and Dynamic Contrast Enhanced MRI (DCE-MRI)
    Yau, C. C.
    Chen, P.
    Curtis, C.
    Murphy, P.
    Parker, G.
    Suttle, A.
    Arumugham, T.
    Hodge, J.
    Dar, M.
    Poon, R.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 122 - 122
  • [4] PHASE I STUDY OF PAZOPANIB (PAZ) IN HEPATOCELLULAR CARCINOMA (HCC): DETERMINATION OF MTD AND EVALUATION OF CLINICAL ACTIVITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMIC (PD) CHANGES IN DYNAMIC CONTRAST ENHANCED MRI (DCE-MRI)
    Yau, Thomas
    Chen, Pei-Jer
    Curtis, C. Martin
    Murphy, Philip S.
    Suttle, A. Benjamin
    Arumugham, Thangam
    Hodge, Jeffrey P.
    Dar, Mohammed M.
    Poon, Ronnie T.
    [J]. HEPATOLOGY, 2009, 50 (04) : 1124A - 1125A
  • [5] Model selection for analysis of dynamic contrast enhanced MRI (DCE-MRI) data.
    Yankeelov T
    Welch E B
    Chakravarthy B
    Lee R
    Freehardt D
    Mayer, I
    Meszoely, I
    Kelly M
    Means-Powell J
    Gore J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S45 - S45
  • [6] Unfolding of Aliased Dynamic Acquisitions for the Acceleration of Breast Dynamic-Contrast Enhanced MRI (DCE-MRI)
    Pineda, F.
    Medved, M.
    Fan, X.
    Karczmar, G.
    [J]. MEDICAL PHYSICS, 2016, 43 (06) : 3391 - 3391
  • [7] Dynamic contrast-enhanced MRI (DCE-MRI) as imaging biomarker in non-small cell lung cancer (NSCLC)
    van den Boogaart, V.
    Smith, E.
    Groen, H.
    Markus, T.
    Kappert, P.
    Backes, W.
    Dingemans, A.
    [J]. EJC SUPPLEMENTS, 2007, 5 (08): : 34 - 34
  • [8] Is it possible to predict the radiosensitivity of cervical cancer using dynamic contrast enhanced MRI (DCE-MRI)?
    Szluha, Lazanyi K.
    Pintye, E.
    Benko, K.
    Der, A.
    Poka, R.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 48 - 48
  • [9] DYNAMIC CONTRAST ENHANCED MRI (DCE-MRI) FOR EVALUATION OF THE EFFECTS OF RENO-PROTECTIVE DRUGS ON RENAL PERFUSION AFTER SWL
    El-Nahas, Ahmed
    El-Ghar, Mohamed Abo
    Taha, Diaa-Eldin
    Elsaadany, Mohamed
    Elshal, Ahmed
    Sheir, Khaled
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E726 - E726
  • [10] Feasibility of dynamic contrast-enhanced MRI (DCE-MRI) based angiogenesis biomarker assessment in advanced NSCLC treated with erlotinib and bevacizumab
    Scheffler, M.
    Ullrich, T.
    Wetzel, T.
    Nogova, L.
    Zander, T.
    Mattonet, C.
    Stoelben, E.
    Engel-Riedel, W.
    Tittgemeyer, M.
    Wolf, J.
    [J]. ONKOLOGIE, 2010, 33 : 284 - 284
12345